StocksMedium•4 November 2026•
1 min read
Teva Raises 2026 Revenue Guidance After Q3 Earnings Beat
Key Facts
1Teva's Q3 earnings exceeded analyst estimates, driven by strong branded drug sales.
2The company raised its 2026 revenue and product sales guidance following the strong performance.
Teva Pharmaceutical reported Q3 earnings that exceeded analyst estimates, fueled by strong sales within its branded drug portfolios. Zacks reported that the company subsequently raised its 2026 revenue and product sales guidance following the performance.
TEVA closed at $41.91 on November 3, 2026, after reaching a day high of $43.34 and a low of $41.54. The upward revision in long-term financial guidance follows the company's increased confidence in its branded product sales growth.